ADMA Biologics (ADMA) Is Down 6.6% After Fraud Allegations and Probe Escalate - What's Changed

Simply Wall St.

May 03

In recent weeks, ADMA Biologics has come under scrutiny after a Culper Research short-seller report alleging channel stuffing and an undisclosed related-party distributor prompted a securities-fraud ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2632604097"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632604097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632604097?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-05-03 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632604097","market":"sg","top_or_hot":-1,"title":"ADMA Biologics (ADMA) Is Down 6.6% After Fraud Allegations and Probe Escalate - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>In recent weeks, ADMA Biologics has come under scrutiny after a Culper Research short-seller report alleging channel stuffing and an undisclosed related-party distributor prompted a securities-fraud ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-down-66-after-fraud-allegations-and-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics (ADMA) Is Down 6.6% After Fraud Allegations and Probe Escalate - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics (ADMA) Is Down 6.6% After Fraud Allegations and Probe Escalate - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-03 17:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-down-66-after-fraud-allegations-and-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent weeks, ADMA Biologics has come under scrutiny after a Culper Research short-seller report alleging channel stuffing and an undisclosed related-party distributor prompted a securities-fraud ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-down-66-after-fraud-allegations-and-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-down-66-after-fraud-allegations-and-p","article_id":"2632604097","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/adma-biologics-adma-is-down-66-after-fraud-allegations-and-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632604097","pubTimestamp":1777800196,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent weeks, ADMA Biologics has come under scrutiny after a Culper Research short-seller report alleging channel stuffing and an undisclosed related-party distributor prompted a securities-fraud investigation by law firm Pomerantz and an analyst downgrade.\nAt the same time, ADMA is preparing to release its first-quarter 2026 results and host a management webcast, meaning investors will soon hear the company’s formal response to these allegations and its broader business outlook...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc","BK4139":"生物科技"},"translate_title":"欺诈指控和调查升级后，ADMA Biologics(ADMA)股价下跌6.6%——发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1.5},"content_text":"In recent weeks, ADMA Biologics has come under scrutiny after a Culper Research short-seller report alleging channel stuffing and an undisclosed related-party distributor prompted a securities-fraud investigation by law firm Pomerantz and an analyst downgrade. At the same time, ADMA is preparing to release its first-quarter 2026 results and host a management webcast, meaning investors will soon hear the company’s formal response to these allegations and its broader business outlook directly. We’ll now examine how the channel stuffing and related-party allegations could influence ADMA Biologics’ previously optimistic long-term investment narrative. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementADMA Biologics Investment Narrative RecapTo own ADMA Biologics, you have to believe in the long term demand for its plasma derived immunoglobulin therapies and the earnings potential of its yield enhancement process and vertically integrated plasma network. The immediate catalyst is the upcoming Q1 2026 report and webcast, where management’s response to the short seller channel stuffing and related party allegations could shape market confidence. The biggest near term risk now is that any formal findings around these claims could affect reported revenue quality. The most relevant recent development here is the announcement of the Q1 2026 earnings release and conference call on 6 May 2026, which gives investors a near term forum to hear ADMA address the allegations directly. This update now matters more than usual, because investors will be weighing management’s explanations against the company’s multiyear revenue guidance, margin expansion story, and the legal review initiated by Pomerantz in light of the Culper Research report. Yet behind ADMA’s growth story, investors should also weigh the heightened risk that any evidence supporting the channel stuffing and related party claims could... Read the full narrative on ADMA Biologics (it's free!)ADMA Biologics' narrative projects $904.6 million revenue and $350.9 million earnings by 2028.Uncover how ADMA Biologics' forecasts yield a $27.25 fair value, a 159% upside to its current price.Exploring Other PerspectivesADMA 1-Year Stock Price Chart Before the Culper report, the most optimistic analysts were assuming ADMA could reach about US$981 million of revenue and US$372 million of earnings by 2028, but if you are counting on that outcome while also recognizing how much it depends on ASCENIV and related immunoglobulin therapies, this short seller driven scrutiny is a reminder that both the bullish and more cautious narratives can shift quickly and are worth comparing side by side.Explore 9 other fair value estimates on ADMA Biologics - why the stock might be worth just $17.00!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ADMA Biologics research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free ADMA Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ADMA Biologics' overall financial health at a glance.Searching For A Fresh Perspective?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Outshine the giants: these 18 early-stage AI stocks could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}